ABSTRACT
OBJECTIVE: The aim of this study was to analyze and identify documented infections and possible risk factors for Clostridioides difficile infections in children with cancer. METHODS: This is a retrospective case-control study, carried out in a pediatric cancer hospital, covering the years 2016-2019. Matching was performed by age and underlying disease, and for each case, the number of controls varied from 1 to 3. Logistic regression models were used to assess risk factors. RESULTS: We analyzed 63 cases of documented infection by C. difficile and 125 controls. Diarrhea was present in all cases, accompanied by fever higher than 38°C in 52.4% of the patients. Mortality was similar among cases (n=4; 6.3%) and controls (n=6; 4.8%; p=0.7). In all, 71% of patients in the case group and 53% in the control group received broad-spectrum antibiotics prior to the infection. For previous use of vancomycin, the Odds Ratio for C. difficile infection was 5.4 (95% confidence interval [95%CI] 2.3-12.5); for meropenem, 4.41 (95%CI 2.1-9.2); and for cefepime, 2.6 (95%CI 1.3-5.1). For the antineoplastic agents, the Odds Ratio for carboplatin was 2.7 (95%CI 1.2-6.2), melphalan 9.04 (95%CI 1.9-42.3), busulfan 16.7 (95%CI 2.1-134.9), and asparaginase 8.97 (95%CI 1.9-42.9). CONCLUSIONS: C. difficile symptomatic infection in children with cancer was associated with previous hospitalization and the use of common antibiotics in cancer patients, such as vancomycin, meropenem, and cefepime, in the last 3 months. Chemotherapy drugs, such as carboplatin, melphalan, busulfan, and asparaginase, were also risk factors.
Subject(s)
Clostridioides difficile , Clostridium Infections , Cross Infection , Neoplasms , Humans , Child , Case-Control Studies , Retrospective Studies , Vancomycin , Cefepime/therapeutic use , Meropenem , Busulfan/therapeutic use , Melphalan/therapeutic use , Asparaginase/therapeutic use , Cancer Care Facilities , Carboplatin/therapeutic use , Cross Infection/epidemiology , Cross Infection/chemically induced , Cross Infection/drug therapy , Anti-Bacterial Agents/therapeutic use , Clostridium Infections/epidemiology , Clostridium Infections/chemically induced , Clostridium Infections/drug therapy , Neoplasms/complications , Risk FactorsABSTRACT
OBJECTIVES: Both linezolid and vancomycin are approved by USFDA and IDSA guidelines for the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus (MRSA) in clinical practice. Baseline creatinine clearance is the criterion for prescribing vancomycin or linezolid for hospital-acquired pneumonia in our institution. However, patients with renal function impairment are far more difficult to manage in intensive care. Thus, the objectives of the study were to compare the clinical efficacy and safety of 600 mg of fixed-dose linezolid with intermittent dose-optimised vancomycin in hospital-acquired pneumonia due to MRSA and to evaluate parameters of clinical cure. METHODS: Analysis of a review of patients' charts. Patients with creatinine clearance <80 ml/min received 600 mg linezolid/12 h (n = 139, LN cohort), and patients with creatinine clearance ≥80 ml/min received intravenous 15 mg/kg vancomycin/12 h for 1-2 weeks consecutively or 3 weeks in case of bacteremia (n = 152, VC cohort) for management of hospital-acquired pneumonia due to MRSA. RESULTS: A 59% of patients from the LN cohort and 47% of patients from the VC cohort were clinically cured. Administration of systemic steroids (p = 0.0412) and ≥ 80 ml/min creatinine clearance (p = 0.0498) were the independent parameters for the clinical cure of patients. Nephrotoxicity was higher among patients of the VC cohort than the LN cohort (p = 0.0464). Treatment failed in 41% of patients from the LN cohort and in 53% of patients from the VC cohort (p = 0.0200). CONCLUSIONS: A 600 mg of fixed-dose linezolid is an ideal alternative to intermittent dose-optimised vancomycin for better clinical outcomes for patients with hospital-acquired pneumonia due to MRSA, especially for patients with renal impairment.
Subject(s)
Cross Infection , Healthcare-Associated Pneumonia , Methicillin-Resistant Staphylococcus aureus , Pneumonia, Staphylococcal , Renal Insufficiency , Humans , Adult , Linezolid/therapeutic use , Vancomycin/therapeutic use , Vancomycin/adverse effects , Anti-Bacterial Agents , Retrospective Studies , Creatinine/therapeutic use , Pneumonia, Staphylococcal/drug therapy , Pneumonia, Staphylococcal/chemically induced , Cross Infection/drug therapy , Cross Infection/chemically induced , Healthcare-Associated Pneumonia/drug therapy , Treatment Outcome , Renal Insufficiency/complications , Renal Insufficiency/chemically induced , HospitalsABSTRACT
BACKGROUND: Probiotic prophylaxis for Clostridioides difficile infection (CDI) is controversial stemming from deficits in strain and disease specificity considerations and concern for adverse effects. Here risk for healthcare facility-onset CDI (HO-CDI) dependent on concomitant antibiotic and infectious indication is assessed to identify opportunities for targeted prophylaxis. METHODS: Retrospective matched-cohort study from January 2016 through March 2019. Patient-admissions administered high risk antibiotics were categorized by Saccharomyces boulardii administration and matched 1:1 to non-recipients. Unadjusted and adjusted HO-CDI risk estimated using Cox proportional hazards regression. RESULTS: S. boulardii administration was associated with 48% risk reduction for HO-CDI compared to non-recipients (aHR 0.52, 95% CI: 0.31-0.87). Patient-admissions administered antibiotics and S. boulardii for a pneumonia indication exhibited a 57% reduction in risk for HO-CDI (aHR 0.43, 95% CI: 0.19-0.95). Administration of S. boulardii with ceftriaxone was associated with a 76% reduced risk of HO-CDI (aHR 0.24, 95% CI: 0.11-0.53) compared to ceftriaxone without S. boulardii, number needed to treat of 100. CONCLUSIONS: S. boulardii administration is associated with a significant HO-CDI risk reduction for inpatients receiving antibiotics associated with CDI. Institutions interested in targeted use of S. boulardii to limit potential adverse effects may consider prophylaxis for inpatients with pneumonia or receiving ceftriaxone.
Subject(s)
Clostridioides difficile , Clostridium Infections , Communicable Diseases , Cross Infection , Saccharomyces boulardii , Humans , Anti-Bacterial Agents/adverse effects , Ceftriaxone/therapeutic use , Retrospective Studies , Cohort Studies , Clostridium Infections/drug therapy , Clostridium Infections/prevention & control , Saccharomyces cerevisiae , Delivery of Health Care , Cross Infection/drug therapy , Cross Infection/prevention & control , Cross Infection/chemically inducedABSTRACT
BACKGROUND: This study aimed to evaluate the utility of a commercial kit used to measure serum vancomycin concentrations to determine vancomycin concentrations in cerebrospinal fluid (CSF) samples and evaluate CSF penetration when administered as a continuous high-dose infusion in patients with nosocomial ventriculitis. METHODS: This study included patients with external ventricular drain infection who were admitted to the intensive care unit between January 2018 and September 2020. After validation, CSF samples from 33 patients were collected. All patients received 30 mg/kg of vancomycin as a loading dose followed by 60 mg/kg as a maintenance dose in continuous infusion; all CSF samples were collected at least 48 hours after the first dose. RESULTS: Thirty-three patients were enrolled in this study. The median serum creatinine level was 0.66 mg/dL (0.5-0.92; n = 30), and median creatinine clearance was 119.2 mL/min (64.6-138.4; n = 13). The median serum vancomycin 24-hour area under the curve (AUC24h) was 838 mg*h/L (515-1010). The median CSF vancomycin concentration was 5.20 mg/L (1.95-12.4). Median serum vancomycin concentration was 34.9 mg/L (21.47-42.1), and median CSF/serum ratio was 18.6% (8.4-41.5). Acute renal injury occurred in 21% (n = 7) of the patients by the end of the therapy. In addition, the vancomycin CSF/serum ratio was positively correlated with the median serum creatinine level (r = 0.670; P = 0.004). CONCLUSIONS: Commercial vancomycin kits used to measure serum samples may be used to evaluate vancomycin concentrations in the CSF. Vancomycin penetration into CSF was 18.6%.
Subject(s)
Cerebral Ventriculitis , Cross Infection , Anti-Bacterial Agents , Cerebral Ventriculitis/chemically induced , Cerebral Ventriculitis/drug therapy , Cross Infection/chemically induced , Cross Infection/drug therapy , Humans , Intensive Care Units , VancomycinABSTRACT
COVID-19 has now spread globally, and 10-20% of the cases are thought to proceed to a severe condition. However, information on COVID-19 in immunodeficient patients remains limited. We treated a 56-year-old man who developed COVID-19 after chemotherapy for mantle cell lymphoma. After 1 month of prolonged fever, the patient's respiratory condition deteriorated rapidly, and he died. COVID-19 in immunocompromised patients after chemotherapy, even with mild symptoms, can cause rapid immune reconstitution and respiratory deterioration. Therefore, caution is advised until negative PCR test results for SARS-CoV-2 are confirmed.
Subject(s)
Bone Marrow Failure Disorders/chemically induced , COVID-19/etiology , Cross Infection/chemically induced , Lymphoma, Mantle-Cell/drug therapy , SARS-CoV-2/isolation & purification , Bone Marrow Failure Disorders/complications , COVID-19/diagnostic imaging , Cross Infection/complications , Cross Infection/etiology , Humans , Immunocompromised Host , Lymphoma, Mantle-Cell/complications , Lymphoma, Mantle-Cell/immunology , Male , Middle Aged , Pharynx/virology , Polymerase Chain Reaction , Radiography, Thoracic , SARS-CoV-2/genetics , Tomography, X-Ray Computed , COVID-19 Drug TreatmentABSTRACT
BACKGROUND: Clostridium difficile infection is one of the most common causes of diarrhea in healthcare facilities. More studies are needed to identify patients at high risk of C difficile infection in our community. OBJECTIVES: Estimate the prevalence of C difficile infection among adult patients and evaluate the risk factors associated with infection. DESIGN: Retrospective record review. SETTING: Tertiary academic medical center in Jeddah. PATIENTS AND METHODS: Eligible patients were adults (≥18 years old) with confirmed C difficile diagnosis between January 2013 and May 2018. MAIN OUTCOME MEASURES: Prevalence rate and types of risk factors. SAMPLE SIZE: Of 1886 records, 129 patients had positive lab results and met the inclusion criteria. RESULTS: The prevalence of C difficile infection in our center over five years was 6.8%. The mean (SD) age was 56 (18) years, and infection was more prevalent in men (53.5%) than in women (46.5%). The most common risk factors were use of proton-pump inhibitors (PPI) and broad-spectrum antibiotics. The overlapping exposure of both PPIs and broad-spectrum antibiotics was 56.6%. There was no statistically significant difference between the type of PPI (P=.254) or antibiotic (P=.789) and the onset of C difficile infection. CONCLUSION: The overall C difficile infection prevalence in our population was low compared to Western countries. The majority of the patients who developed C difficile infection were using PPIs and/or antibiotics. No differences were observed in the type of antibiotic or PPI and the onset of C difficile infection development. Appropriate prescribing protocols for PPIs and antibiotics in acute settings are needed. LIMITATIONS: Single center and retrospective design. CONFLICT OF INTEREST: None.
Subject(s)
Anti-Bacterial Agents/adverse effects , Clostridium Infections/epidemiology , Cross Infection/epidemiology , Diarrhea/epidemiology , Proton Pump Inhibitors/adverse effects , Academic Medical Centers , Adult , Aged , Clostridium Infections/chemically induced , Cross Infection/chemically induced , Diarrhea/chemically induced , Diarrhea/microbiology , Female , Humans , Male , Middle Aged , Prevalence , Retrospective Studies , Risk Factors , Saudi Arabia/epidemiologyABSTRACT
Influenza-related severe pneumonia and acute respiratory distress syndrome (ARDS) are severe threats to human health. The objective of this study was to assess the effects of systematic corticosteroid therapy in patients with pneumonia or ARDS. The PubMed, EMBASE, Web of Science and SCOPUS databases were searched up to July, 2019. Nineteen studies including 6637 individuals were identified, and fifteen studies (6427 patients) were included in the meta-analysis of mortality. Eighteen were observational studies and one was a randomized controlled trial (RCT). The meta-analysis results showed that corticosteroid therapy was associated with significantly higher mortality (OR 1.53, 95% CI [1.16, 2.01]) and incidence of nosocomial infection (OR 3.15, 95% CI [1.54, 6.45]). Subgroup analysis showed that among patients with unadjusted estimates, the odds of mortality were higher in patients receiving corticosteroid treatment (OR 1.98, 95% CI [1.23, 3.17]), however, among patients with adjusted estimates, the result showed no statistically significant difference between corticosteroid group and control group (OR 1.31, 95% CI [0.95, 1.80]). Current data do not support the routine use of corticosteroids in patients with influenza severe pneumonia or ARDS. RCTs are needed to provide more robust evidence.
Subject(s)
Adrenal Cortex Hormones/therapeutic use , Influenza, Human/drug therapy , Pneumonia/drug therapy , Pneumonia/virology , Respiratory Distress Syndrome/drug therapy , Respiratory Distress Syndrome/virology , Adolescent , Adrenal Cortex Hormones/pharmacology , Adult , Child , Child, Preschool , Cohort Studies , Cross Infection/chemically induced , Female , Humans , Influenza, Human/mortality , Length of Stay , Male , Middle Aged , Pneumonia/mortality , Respiration, Artificial , Respiratory Distress Syndrome/mortality , Time Factors , Treatment Outcome , Virus Shedding , Young AdultABSTRACT
Clostridioides difficile infection (CDI) is a health care-associated infection associated with significant morbidity and cost, with highly varied risk across populations. More effective, risk-based prevention strategies are needed. Here, we investigate risk factors for hospital-associated CDI in a large integrated health system. In a retrospective cohort of all adult admissions to 21 Intermountain Healthcare hospitals from 2006 to 2012, we identified all symptomatic (i) hospital-onset and (ii) health care-facility-associated, community-onset CDI. We then evaluated the risk associated with antibiotic exposure, including that of specific agents, using multivariable logistic regression. A total of 2,356 cases of CDI among 506,068 admissions were identified (incidence, 46.6 per 10,000). Prior antibiotic use was the dominant risk factor, where for every antibiotic day of therapy prior to the index admission, the odds of subsequent CDI increased by 12.8% (95% confidence interval [CI], 12.2 to 13.4%; P < 0.0001). This was a much stronger association than was inpatient antibiotic exposure (odds ratio [OR], 1.007 [95% CI, 1.005 to 1.009]; P < 0.0001). The highest-risk antibiotics included second-generation and later cephalosporins (especially oral), carbapenems, fluoroquinolones, and clindamycin, while doxycycline and daptomycin were associated with a lower CDI risk. We concluded that cumulative antibiotic exposure prior to admission is the greatest contributor to the risk of subsequent CDI. Most classes of antibiotics carry some risk, which varies by drug and route. This information may be useful for antimicrobial stewardship efforts.
Subject(s)
Adaptation, Physiological/drug effects , Anti-Bacterial Agents/adverse effects , Antimicrobial Stewardship , Clostridioides difficile/drug effects , Clostridium Infections/drug therapy , Cross Infection/microbiology , Adaptation, Physiological/genetics , Anti-Bacterial Agents/therapeutic use , Carbapenems/adverse effects , Carbapenems/therapeutic use , Cephalosporins/adverse effects , Cephalosporins/therapeutic use , Clindamycin/adverse effects , Clindamycin/therapeutic use , Clostridioides difficile/genetics , Cross Infection/chemically induced , Cross Infection/drug therapy , Daptomycin/adverse effects , Daptomycin/therapeutic use , Doxycycline/adverse effects , Doxycycline/therapeutic use , Drug Resistance, Bacterial/genetics , Female , Fluoroquinolones/adverse effects , Fluoroquinolones/therapeutic use , Humans , Male , Middle Aged , Retrospective StudiesABSTRACT
BACKGROUND: Unnecessary antibiotic use (AU) contributes to increased rates of Clostridioides difficile infection (CDI). The impact of antibiotic restriction on hospital-onset CDI (HO-CDI) has not been assessed in a large group of US acute care hospitals (ACHs). METHODS: We examined cross-sectional and temporal associations between rates of hospital-level AU and HO-CDI using data from 549 ACHs. HO-CDI was defined as a discharge with a secondary International Classification of Diseases, Ninth Revision, Clinical Modification code for CDI (008.45), and treatment with metronidazole or oral vancomycin > 3 days after admission. Analyses were performed using multivariable generalized estimating equation models adjusting for patient and hospital characteristics. RESULTS: During 2006-2012, the unadjusted annual rates of HO-CDI and total AU were 7.3 per 10 000 patient-days (PD) (95% confidence interval [CI], 7.1-7.5) and 811 days of therapy (DOT)/1000 PD (95% CI, 803-820), respectively. In the cross-sectional analysis, for every 50 DOT/1000 PD increase in total AU, there was a 4.4% increase in HO-CDI. For every 10 DOT/1000 PD increase in use of third- and fourth-generation cephalosporins or carbapenems, there was a 2.1% and 2.9% increase in HO-CDI, respectively. In the time-series analysis, the 6 ACHs with a ≥30% decrease in total AU had a 33% decrease in HO-CDI (rate ratio, 0.67 [95% CI, .47-.96]); ACHs with a ≥20% decrease in fluoroquinolone or third- and fourth-generation cephalosporin use had a corresponding decrease in HO-CDI of 8% and 13%, respectively. CONCLUSIONS: At an ecologic level, reductions in total AU, use of fluoroquinolones, and use of third- and fourth-generation cephalosporins were each associated with decreased HO-CDI rates.
Subject(s)
Anti-Bacterial Agents/adverse effects , Clostridioides difficile , Clostridium Infections/epidemiology , Cross Infection/epidemiology , Drug Prescriptions/statistics & numerical data , Adult , Aged , Cephalosporins/therapeutic use , Clostridium Infections/chemically induced , Clostridium Infections/microbiology , Cross Infection/chemically induced , Cross Infection/microbiology , Cross-Sectional Studies , Ecological and Environmental Phenomena , Female , Fluoroquinolones/therapeutic use , Hospitalization/statistics & numerical data , Hospitals/statistics & numerical data , Humans , Interrupted Time Series Analysis , Male , Metronidazole/therapeutic use , Middle Aged , United States/epidemiology , Vancomycin/therapeutic useABSTRACT
BACKGROUND: Clostridium difficile infection (CDI) is one of the leading causes of health-care-associated infections in the USA. There are limited data available regarding CDI in hospitalized patients with inflammatory bowel disease-related ileal pouch. AIMS: This study aimed to evaluate the demographics, clinical features, risk factors, and admission outcomes among hospitalized patients with CDI-related pouchitis (CDP). METHODS: Retrospective chart review was performed for patients who were admitted to our institute for pouchitis between 2013 and 2016 to identify patients with CDP. Logistic regression analysis was performed to assess the risk factors associated with CDP. RESULTS: A total of 160 subjects with pouchitis had a total of 218 admissions during the study period. Primary admission diagnosis was pouchitis or inflammatory bowel disease flare-up for 202 (93%) admissions. Clostridium difficile was tested at least once for 72 patients, and the diagnosis of CDP was established for 16 (10%) patients. All patients with CDP were symptomatic, 13 (81%) had diarrhea, 8 (50%) had abdominal pain, 7 (44%) had nausea/vomiting, and 2 (13%) had gastrointestinal bleeding. On multivariable analysis, only body mass index > 25 (OR 0.25, 95% CI 0.06-0.94, p = 0.048) was significantly associated with decreased risk of CDP. No patients in CDP cohort were admitted to ICU, died at the hospital, or readmitted in 30 days after the discharge. CONCLUSIONS: In our cohort, obesity was associated with low risk of CDP among hospitalized patients with pouchitis. This finding warrants further validation in prospective studies.
Subject(s)
Anti-Bacterial Agents/adverse effects , Clostridioides difficile , Cross Infection/chemically induced , Enterocolitis, Pseudomembranous/chemically induced , Obesity/complications , Postoperative Complications/chemically induced , Pouchitis/drug therapy , Adult , Aged , Aged, 80 and over , Colonic Pouches/microbiology , Cross Infection/microbiology , Enterocolitis, Pseudomembranous/microbiology , Female , Hospitalization , Humans , Male , Middle Aged , Obesity/microbiology , Obesity/surgery , Postoperative Complications/microbiology , Pouchitis/microbiology , Retrospective Studies , Risk Factors , Young AdultABSTRACT
Hospital-acquired infections have been recognized as a significant factor in increased morbidity and mortality across our health system. Unique to infections associated with inpatient psychiatric hospitalization is the additional hypothesized association of the role that antipsychotic agents and/or underlying disease may play in an increased risk for infection. In this paper, we explore the types of infections diagnosed in an inpatient psychiatric hospital, the demographics of the patients infected, and whether or not the patient was on antipsychotic agents at the time of infection.
Subject(s)
Anti-Bacterial Agents/adverse effects , Cross Infection/chemically induced , Drug Prescriptions , Hospitalization/trends , Hospitals, Psychiatric/trends , Mental Disorders/drug therapy , Antipsychotic Agents/adverse effects , Cross Infection/epidemiology , Humans , Mental Disorders/epidemiology , Risk FactorsABSTRACT
BACKGROUND AND PURPOSE: Increased sympathetic tone causes hypertension after intracerebral hemorrhage, and blood pressure reduction has been studied as a way to decrease hemorrhage growth and improve outcomes. It is unknown if the antihypertensive used to achieve blood pressure goals influences either. Because sympatholytic drugs reduce death and infection in animal models, we hypothesized that labetalol would improve outcomes compared with nicardipine. METHODS: Prospective data from a single center were retrospectively reviewed. Patients receiving labetalol, nicardipine, or both during their first 3 days of hospitalization were included. Outcomes included in-hospital death; discharge modified Rankin Score >2; and in-hospital urinary tract infection, pneumonia, or bacteremia. Patients were compared with propensity scoring and analyzed with linear models adjusted for significant confounders. RESULTS: Of 1066 admissions, 525 were treated with labetalol or nicardipine and are included; 229 (43.6%) received labetalol, 107 (20.4%) received nicardipine, and 189 (36.0%) received both. Mortality and infection rates were 40.2% and 15.8%, respectively, 77.2% had a modified Rankin Score >2. After adjustment, compared with nicardipine alone, labetalol alone was associated with infection (odds ratio, 3.12; confidence interval, 1.27-7.64; P=0.013) but not when combined with nicardipine (odds ratio, 2.44; confidence interval, 0.98-6.07; P=0.055). Labetalol, with or without nicardipine, was not associated with death or discharge modified Rankin Score >2. CONCLUSIONS: Compared with nicardipine, labetalol was associated with increased in-hospital infections, but not mortality or modified Rankin Score >2. These findings do not support our hypothesis that labetalol use improves outcomes relative to nicardipine in intracerebral hemorrhage.
Subject(s)
Cerebral Hemorrhage/drug therapy , Cerebral Hemorrhage/epidemiology , Cross Infection/chemically induced , Cross Infection/epidemiology , Labetalol/adverse effects , Nicardipine/therapeutic use , Adrenergic beta-Antagonists/adverse effects , Adrenergic beta-Antagonists/therapeutic use , Adult , Aged , Antihypertensive Agents/adverse effects , Antihypertensive Agents/therapeutic use , Cerebral Hemorrhage/diagnosis , Cross Infection/diagnosis , Female , Humans , Hypertension/drug therapy , Hypertension/epidemiology , Male , Middle Aged , Prospective Studies , Retrospective StudiesABSTRACT
BACKGROUND: The inhibition of gastric acid secretion with ranitidine is frequently prescribed off-label to newborns admitted to neonatal intensive care units (NICU). Some studies show that the use of inhibitors of gastric acid secretion (IGAS) may predispose to infections and necrotising enterocolitis (NEC), but there are few data to confirm this association. This study aimed to compare the rates of neonatal infections and NEC among preterm infants (<37 weeks gestation) hospitalised in a NICU exposed or not to treatment with ranitidine. METHODS: A retrospective cohort study was conducted with all consecutive preterm newborns admitted to a NICU between August-2014 and October-2015. The rates of infection, NEC, and death of newborns exposed or not to ranitidine were recorded. RESULTS: A total of 300 newborns were enrolled, of which 115 had received ranitidine and 185 had not. The two groups were similar with regard to the main demographic and clinical characteristics. Forty-eight (41.7%) of the 115 infants exposed to ranitidine and 49 (26.5%) of the 185 infants not exposed were infected (RR = 1.6, 95%CI 1.1-2.2, p = 0.006). The late onset (>48 h) blood culture positive infection rate was higher in the group exposed to ranitidine than in the untreated group (13.0% vs. 3.8%, p = 0.001). There was no significant association between the use of ranitidine and NEC (Bell stage >II) (p = 0.36). The mortality rate risk was 4-fold higher in infants receiving ranitidine (16.5% vs. 8.6%, p < 0.001). CONCLUSION: Ranitidine use in neonates was associated with an increased risk of infections and mortality, but not with NEC.
Subject(s)
Cross Infection/epidemiology , Enterocolitis, Necrotizing/epidemiology , Ranitidine/adverse effects , Adult , Brazil/epidemiology , Cohort Studies , Cross Infection/chemically induced , Cross Infection/etiology , Enterocolitis, Necrotizing/chemically induced , Enterocolitis, Necrotizing/etiology , Female , Gestational Age , Hospital Mortality , Humans , Infant , Infant, Newborn , Infant, Premature , Intensive Care Units, Neonatal/statistics & numerical data , Male , Ranitidine/administration & dosage , Ranitidine/therapeutic use , Retrospective StudiesABSTRACT
BACKGROUND/AIMS: Although proton pump inhibitors (PPIs) have been widely used for the prevention and treatment of stress gastric ulcers in hospital settings, there are concerns that PPIs increase the risk of Clostridium difficile infection (CDI). However, little is known about the risk of CDI following PPI and histamine-2 receptor antagonist (H2RA) use. We evaluated the comparative hospital-acquired CDI occurrence risk associated with the concurrent use of PPIs versus H2RAs. METHODS: A systematic search of PubMed, MEDLINE/Ovid, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Science, and Google Scholar through August 19, 2016, identified 12 studies that reported the hospital-acquired CDI occurrence following H2RA and PPI use for the prevention and treatment of stress gastric ulcers. Random-effects pooled odds ratios and 95% confidence intervals were estimated. Heterogeneity was measured using I², and a meta-regression analysis was conducted. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was used to assess the overall quality of the evidence. RESULTS: A total of 74,132 patients from 12 observational studies were analyzed. Compared to H2RAs, PPIs increased the risk of CDI by 38.6% (pooled odds ratio, 1.386; 95% confidence interval, 1.152 to 1.668; p=0.001; I²=42.81%). Subgroup analyses of the purpose of study medication use, study site, and study design confirmed the consistency of a greater CDI risk with PPIs than with H2RAs. The overall quality of evidence was rated as low. CONCLUSIONS: The use of PPIs for both the prevention and treatment of stress ulcers was associated with a 38.6% increased risk of hospital-acquired CDI occurrence compared to H2RA use.
Subject(s)
Clostridium Infections/prevention & control , Cross Infection/prevention & control , Histamine Agonists/adverse effects , Proton Pump Inhibitors/adverse effects , Stomach Ulcer/drug therapy , Aged , Clostridioides difficile , Clostridium Infections/chemically induced , Clostridium Infections/microbiology , Cross Infection/chemically induced , Cross Infection/microbiology , Female , Humans , Male , Odds Ratio , Risk Factors , Stomach Ulcer/prevention & control , Stomach Ulcer/psychology , Stress, Psychological/complications , Treatment OutcomeABSTRACT
BACKGROUND: Previous studies of the association between antibiotic exposure and risk of hospital-acquired Clostridium difficile-associated infection (CDI) have not fully accounted for patient severity of illness, and competing risks. AIM: To determine the potential effects of interventions on hospital-acquired CDI risk. METHODS: All adults admitted to a teaching hospital between 2004 and 2014 for more than two days were included. Exposures to all antibiotics and cases of CDI were determined. Patients were followed until discharge from hospital, death, or acquisition of hospital-acquired CDI (defined as positive toxin assay in unformed stool >2 days following admission). Multivariable proportional hazards competing-risks modelling with time-dependent covariates was used, accounting for patient severity of illness using the Escobar model. FINDINGS: In all, 208,104 patients were studied. Hospital-acquired CDI risk was 0.46 events per 1000 patient-days, decreasing significantly during the study period. Compared to the 5th percentile hospital death risk (0.02%), patients with a 50% risk of death in hospital had an adjusted hazard ratio (aHR) of hospital-acquired CDI of 5.5. Exposure to some antibiotics significantly increased hospital-acquired CDI risk, being highest for carbapenems (aHR: 1.47 after one week of continuous exposure) and intravenous vancomycin (aHR: 1.53). On the ward, sharing a room with other patients newly diagnosed with CDI significantly increased the risk of subsequent disease (aHR: 1.16 on CDI diagnosis day). CONCLUSION: The primary determinant of hospital-acquired CDI was patient severity of illness. Exposure to both antibiotics and other patients with CDI significantly increased the subsequent risk of hospital-acquired CDI but this risk was small relative to patient severity of illness.
Subject(s)
Clostridioides difficile/isolation & purification , Clostridium Infections/epidemiology , Colitis/epidemiology , Cross Infection/epidemiology , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Clostridium Infections/chemically induced , Clostridium Infections/microbiology , Clostridium Infections/transmission , Colitis/chemically induced , Colitis/microbiology , Cross Infection/chemically induced , Cross Infection/microbiology , Cross Infection/transmission , Drug Utilization , Environmental Exposure , Female , Hospitals, Teaching , Humans , Male , Middle Aged , Severity of Illness Index , Young AdultABSTRACT
PURPOSE: Results of a pharmacist-driven protocol to decrease proton pump inhibitor (PPI) use in non-intensive care unit (ICU) hospitalized adults are presented. METHODS: This concurrent preintervention and postintervention study included subjects at least 18 years of age receiving PPIs while hospitalized in general medical or surgical beds. Patients were identified for inclusion in the postintervention group using a daily list of hospitalized patients with active PPI orders. A pharmacist evaluated these subjects for PPI appropriateness, and then recommended discontinuing or changing PPIs to histamine H2-receptor antagonists. Per protocol, the pharmacist could change PPIs to H2-antagonists if prescribers did not respond to recommendations. Preintervention group patients were gathered retrospectively and treated as the retrospective control group. Patients were excluded if they had cumulative ICU or ICU step-down stays of at least two days, had predefined appropriate indications for PPIs, or were not evaluated within one day of PPI orders. The primary outcome was the rate of PPI use. Secondary objectives included rates of prescriber acceptance of pharmacist recommendations and hospital-onset Clostridium difficile infections (HO-CDI). RESULTS: PPIs were discontinued in 66.0% (n = 62) of postintervention group patients compared to 41.1% (n = 39) of the preintervention group (absolute risk reduction, 24.9%; p = 0.001). In the postintervention group, 31.9% (n = 30) of recommendations were accepted, whereas 11.7% (n = 11) were rejected. No subjects in either group were diagnosed with HO-CDI during the study period. CONCLUSION: The pharmacist-driven protocol described in this study decreased PPI use in non-ICU hospitalized adults.
Subject(s)
Hospitalization , Inappropriate Prescribing/adverse effects , Pharmacists , Professional Role , Proton Pump Inhibitors/adverse effects , Adult , Aged , Aged, 80 and over , Clostridioides difficile/drug effects , Clostridium Infections/chemically induced , Clostridium Infections/epidemiology , Critical Care , Cross Infection/chemically induced , Cross Infection/epidemiology , Female , Hospitalization/trends , Hospitals, Community/methods , Hospitals, Community/trends , Humans , Inappropriate Prescribing/trends , Male , Middle Aged , Pharmacists/trends , Pharmacy Service, Hospital/methods , Pharmacy Service, Hospital/trends , Proton Pump Inhibitors/administration & dosage , Retrospective StudiesABSTRACT
BACKGROUND Healthcare-associated infections (HAIs) cause significant morbidity in critically ill patients. An underappreciated but potentially modifiable risk factor for infection is sedation strategy. Recent trials suggest that choice of sedative agent, depth of sedation, and sedative management can influence HAI risk in mechanically ventilated patients. OBJECTIVE To better characterize the relationships between sedation strategies and infection. METHODS Systematic literature review. RESULTS We found 500 articles and accepted 70 for review. The 3 most common sedatives for mechanically ventilated patients (benzodiazepines, propofol, and dexmedetomidine) have different pharmacologic and immunomodulatory effects that may impact infection risk. Clinical data are limited but retrospective observational series have found associations between sedative use and pneumonia whereas prospective studies of sedative interruptions have reported possible decreases in bloodstream infections, pneumonia, and ventilator-associated events. CONCLUSION Infection rates appear to be highest with benzodiazepines, intermediate with propofol, and lowest with dexmedetomidine. More data are needed but studies thus far suggest that a better understanding of sedation practices and infection risk may help hospital epidemiologists and critical care practitioners find new ways to mitigate infection risk in critically ill patients. Infect Control Hosp Epidemiol 2016;1-9.
Subject(s)
Benzodiazepines/pharmacology , Cross Infection/chemically induced , Hypnotics and Sedatives/pharmacology , Animals , Benzodiazepines/immunology , Clinical Trials as Topic , Critical Care , Disease Models, Animal , Humans , Hypnotics and Sedatives/immunology , Propofol/immunology , Propofol/pharmacology , Rats , Respiration, Artificial , Risk FactorsABSTRACT
No disponible
Subject(s)
Humans , Male , Aged , Chryseobacterium/metabolism , Chryseobacterium/physiology , Chryseobacterium/pathogenicity , Flavobacterium/metabolism , Flavobacterium/physiology , Flavobacterium/pathogenicity , Respiration, Artificial/instrumentation , Respiration, Artificial/methods , Respiration, Artificial , Pneumonia/chemically induced , Pneumonia, Ventilator-Associated/diagnosis , Pneumonia, Ventilator-Associated/prevention & control , Pneumonia, Ventilator-Associated/therapy , Cross Infection/chemically induced , Cross Infection/pathology , Cross Infection/therapy , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/therapeutic use , Diagnosis, Differential , AgedABSTRACT
BACKGROUND/AIMS: Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) are commonly prescribed for stress ulcer prophylaxis (SUP) in critically ill patients. Several studies have suggested that the use of PPIs is a potential risk factor for Clostridium difficile infection (CDI). We compared the incidences of CDI in the PPI group and H2RA group for SUP in critically ill patients. METHODS: From August 2005 to July 2012, the incidences of CDI were retrospectively analyzed in patients who were admitted directly to intensive care units and stayed for more than 3 days. SUP-related CDI was defined as a CDI diagnosed during the SUP period. Patient clinical data were analyzed to identify potential risk factors for SUP-related CDI. RESULTS: Of the 1,005 patients enrolled (444 patients received PPI and 561 received H2RA), 38 (3.8%) were diagnosed with SUP-related CDI. The incidence of SUP-related CDI was considerably higher in patients who received PPI than in those who received H2RA (6.7% vs 1.8%). PPI use for SUP (odds ratio [OR], 3.3; confidence interval [CI], 1.5 to 7.1; p=0.003) and diabetes mellitus (OR, 2.3; CI, 1.2 to 4.7; p=0.019) were independent risk factors for SUP-related CDI. CONCLUSIONS: PPI therapy is associated with a higher risk of SUP-related CDI than H2RA therapy in critically ill patients.